Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)

Exclusion Criteria

• •1. Females of childbearing potential (those who are not surgically sterile, postmenopausal or using a reliable birth control method) will be excluded from the study.
• •2. Any allergic component or contraindication to the study medications
• •3. Pachymetry of 600 microns or greater
• •4. Systemic corticosteroids not on a stable regimen within 30 days of screening visit.
• •5. Any concurrent topical agents that can not be discontinued during the course of the trial (natural tears are acceptable)
• •6. Significant ocular surface abnormalities
• •7. Patients with any form of glaucoma other than ocular hypertension or open-angle glaucoma
• •8. Patients who have been on an investigational therapy within 30 days prior to screening visit
• •9. History of ocular trauma within the past 3 months
• •10. Intraocular surgery within the past 3 months
• •11. Ocular laser surgery within the past 3 months
• •12. Any abnormality preventing reliable applanation tonometry of either eye
• •13. VA of 20/200 or greater in either eye
• •14. History or evidence of clinically significant illness or conditions which would make the patient, in the opinion of the investigator, not suitable for the study